Roquefort Therapeutics PLC Issue of Warrants (8571P)
June 22 2022 - 11:42AM
UK Regulatory
TIDMROQ
RNS Number : 8571P
Roquefort Therapeutics PLC
22 June 2022
22 June 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Issue of Warrants
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech
company focused on early-stage opportunities in the biotechnology
sector, announces the following issue of warrants to recently
appointed Non-Executive Directors and an advisor to the Board:
Position Number of Warrants Total Number
Name Issued of Warrants Held
After Issue
Non-Executive
Ms Jean Duvall Director 300,000 300,000
--------------- ------------------- ------------------
Non-Executive
Dr Simon Sinclair(1) Director 300,000 300,000
--------------- ------------------- ------------------
Prof. Trevor Jones Board Advisor 300,000 300,000
--------------- ------------------- ------------------
(1) Warrants held in the name of Livingstone Investment Holdings
Ltd, a company in which Dr Sinclair has a beneficial interest
The warrants have been issued in relation to the appointment of
the abovenamed earlier this year and form part of their annual
remuneration package.
The warrants have a term of 5 years and are exercisable at a
price of 15 pence, with 50% exercisable after 12 months and the
balance exercise after 24 months.
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
+44 (0)20 7466
Optiva Securities Limited (Broker) 5000
+44 (0)20 3411
Christian Dennis 1881
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to
partnering or selling to big pharma. The Company is a pre-clinical
biotech company focused on developing first in class Midkine
targeting drugs for the treatment of cancer.
Through extensive research resulting in validation through
publication in over 1,000 scientific journals, Roquefort
Therapeutics has identified the potential to exploit the broad
therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an
exclusive licence to the largest global IP portfolio on Midkine.
The Midkine blocking drug development markets have significant
global market potential (in the multi-billion dollars). Roquefort
Therapeutic's pre-clinical program is currently underway with an
initial focus on cancer.
This announcement contains inside information for the purposes
of Article 7 of the UK version of Market Regulation (EU) No
596/2014 on Market Abuse as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018, as amended ("UK
MAR").
The notifications below, made in accordance with the
requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Jean Duvall
--------------------------------- -----------------------------------------
Reason for the notification
2
----------------------------------------------------------------------------
a) Position/status Non-Executive Director
--------------------------------- -----------------------------------------
b) Initial notification Initial
/Amendment
--------------------------------- -----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Roquefort Therapeutics plc
--------------------------------- -----------------------------------------
b) LEI 254900P4SISIWOR9RH34
--------------------------------- -----------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Warrants (exercise price of 15 pence)
financial instrument,
type of instrument ISIN: GB00BMDQ2T15
Identification code
--------------------------------- -----------------------------------------
b) Nature of the transaction Issue of warrants
--------------------------------- -----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------------------------------- ---------------------------- -----------
15 pence per share 300,000
------------------------------------------------------------------- -----------
d Aggregated information
- Aggregated volume * 300,000
- Price
* 15p
--------------------------------- -----------------------------------------
e) Date of the transactions 22 June 2022
--------------------------------- -----------------------------------------
f) Place of the transactions Outside a trading venue
--------------------------------- -----------------------------------------
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Simon Sinclair
--------------------------------- -----------------------------------------
Reason for the notification
2
----------------------------------------------------------------------------
a) Position/status Non-Executive Director
--------------------------------- -----------------------------------------
b) Initial notification Initial
/Amendment
--------------------------------- -----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Roquefort Therapeutics plc
--------------------------------- -----------------------------------------
b) LEI 254900P4SISIWOR9RH34
--------------------------------- -----------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
a) Description of the Warrants (exercise price of 15 pence)
financial instrument,
type of instrument ISIN: GB00BMDQ2T15
Identification code
--------------------------------- -----------------------------------------
b) Nature of the transaction Issue of warrants
--------------------------------- -----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------------------------------- ---------------------------- -----------
15 pence per share 300,000
------------------------------------------------------------------- -----------
d Aggregated information
- Aggregated volume * 300,000
- Price
* 15p
--------------------------------- -----------------------------------------
e) Date of the transactions 22 June 2022
--------------------------------- -----------------------------------------
f) Place of the transactions Outside a trading venue
--------------------------------- -----------------------------------------
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEDZGZVKZGGZZM
(END) Dow Jones Newswires
June 22, 2022 11:42 ET (15:42 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jul 2023 to Jul 2024
